RxDoctor Payments Data

Connor Petty

Nurse Practitioner · Ardmore, OKNPI 1497539498

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,054 of the $3,948 with a category attached, or 77.4%. 23 manufacturers reported payments, led by Livanova USA, Inc. at 50.9% of the total. Reporting peaked in 2024 at $2,920 and has fallen 77.8% since, to $648 in 2025. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,948in general payments, 2019–2025

Across 134 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • UCB, Inc.$365
  • AbbVie$252
  • Teva Pharmaceuticals USA, Inc.$231
  • Neurocrine Biosciences, Inc.$189
  • SK Life Science, Inc.$149
  • plus $754 from 17 others

What the payments were for

  • Travel & lodging$89423%
  • Food & beverage$3,05477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,948 in reported general payments places this provider in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate41$68,039
UbrelvyUbrogepant35$37,720
BriviactBrivaracetam27$36,415
QuliptaAtogepant28$32,665
Lamotrigine174$9,536
Aimovig AutoinjectorErenumab-Aooe12$9,002
Pregabalin41$7,886
Gabapentin304$6,056
Memantine Hcl222$6,035
Duloxetine Hcl121$5,720
Donepezil Hcl209$5,274
Levetiracetam107$5,175
Topiramate131$5,107
Primidone159$3,020
Divalproex Sodium91$2,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$252$70,38563 claims
PfizerNurtec Odt$31$68,03941 claims
UCB, Inc.Briviact$365$36,41527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →